Investigating Critical Issues in the Management of Patients with Severe Asthma

Join us for a virtual, livestream lecture!

 

Tuesday, October 6 2020
7:30 PM – 8:30 PM EDT

 

AGENDA

7:15 PM – 7:30 PM       Welcome and Sign on to Livestream
7:30 PM – 8:20 PM       Practitioner’s EdgeSM Scientific Session
8:20 PM – 8:30 PM       Question & Answer Session

FACULTY

Gary N. Gross, MD
Clinical Professor of Internal Medicine
Southwestern Medical School
Head, Allergy Section
Baylor University Medical Center
Dallas, Texas

PROGRAM OVERVIEW

Despite recent advances in our understanding of the pathophysiology of asthma and a corresponding expansion of targeted treatment modalities, severe asthma care continues to be a challenge in clinical practice. This program is designed to address this issue by imparting clinical knowledge and competence to clinicians that will promote comprehensive assessment and highly personalized treatment of patients whose symptoms meet the criteria for severe asthma. In addition, this initiative is also targeted at providing clinicians with guidance on strategies for using phenotypes and biomarkers to identify patient characteristics in practice, decreasing the use of oral corticosteroids (OCS), and optimally managing patients for the best outcomes.

PROGRAM FORMAT

Practitioner’s EdgeSM Workshops are innovative, interactive meetings that provide attendees with cutting edge medical education in a peer-to-peer discussion setting. Practitioner’s EdgeSM provides the practicing healthcare provider with tools and education that may be utilized immediately in daily practice.

In this Practitioner’s EdgeSM program, case studies will be utilized to illustrate issues related to patients with severe asthma.  Audience participation will be invited via interactive questions interspersed throughout the program. The results of the interactive questions will serve as a catalyst for faculty discussion and best-practice reinforcement.

TARGET AUDIENCE

This educational initiative has been designed for allergists, pulmonologists, specialty nurse practitioners and physician assistants and internal medicine physicians involved in the management of severe asthma.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

  • Review severe asthma phenotypes and endotypes and conduct appropriate biomarker tests to assess phenotypes in patients with severe asthma
  • Evaluate the latest evidence supporting the use of biologic therapies for the management of severe asthma

  • Incorporate into practice the most recent recommendations for the optimal management of patients with severe asthma

  • Implement strategies to minimize the use of OCS in patients with severe asthma

REGISTRATION

There is no registration fee for participating in this activity. To register, click the registration buttons on this page or call Integrity Continuing Education, Inc. at 1-855-835-4004.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must view the livestream activity, participate in program polling questions, and complete the evaluation form at the end of the program. A statement of credit will be issued only upon submission of a completed activity evaluation form and will be sent to you within four weeks of receipt of the completed evaluation.

FEE INFORMATION

There is no fee for this educational activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or info@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Gary N. Gross, MD
Consulting Fees:ALK, Optinose, Regeneron, Sanofi
Speakers’ Bureaus: ALK, Optinose, Regeneron, Sanofi
Contracted Research: Merck, Novartis, Sanofi, TEVA, Westward

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education, Inc. or Sanofi Genzyme and Regeneron Pharmaceuticals. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.

 

Provided by Integrity Continuing Education, Inc.

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

 

Agenda

7:15 PM – 7:30 PM       Welcome and Sign on to Livestream
7:30 PM – 8:20 PM       Practitioner’s EdgeSM Scientific Session
8:20 PM – 8:30 PM       Question & Answer Session

Instructions:
On the day of the program, you may access the event by going to https://live.hybridmeetings.live/live/integrity/tdrbk4vw

There are no fees for participating and receiving CME credit for this activity. For your participation you will be able to receive a maximum of 1.0 AMA PRA Category 1 CME creditTM. To do so, you must participate in the virtual live stream activity and complete the posttest and evaluation following the event. A statement of credit will be issued only upon submission of a completed activity evaluation form.